172 related articles for article (PubMed ID: 15975669)
1. Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes.
Erdmann E
Int J Cardiol; 2006 Feb; 107(2):147-53. PubMed ID: 15975669
[TBL] [Abstract][Full Text] [Related]
2. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.
Matthews DR; Charbonnel BH; Hanefeld M; Brunetti P; Schernthaner G
Diabetes Metab Res Rev; 2005; 21(2):167-74. PubMed ID: 15386821
[TBL] [Abstract][Full Text] [Related]
3. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
4. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
Seufert J
Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074
[TBL] [Abstract][Full Text] [Related]
5. Metformin and pioglitazone: Effectively treating insulin resistance.
Staels B
Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
[TBL] [Abstract][Full Text] [Related]
6. Microalbuminaria and the risk of atherosclerosis. Clinical epidemiological and physiological investigations.
Jensen JS
Dan Med Bull; 2000 Apr; 47(2):63-78. PubMed ID: 10822799
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
Strowig SM; Raskin P
Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
[TBL] [Abstract][Full Text] [Related]
12. Lowering the threshold for defining microalbuminuria: effects of a lifestyle-metformin intervention in obese "normoalbuminuric" non-diabetic subjects.
Cubeddu LX; Alfieri AB; Hoffmann IS
Am J Hypertens; 2008 Jan; 21(1):105-10. PubMed ID: 18091752
[TBL] [Abstract][Full Text] [Related]
13. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
Wilcox R; Kupfer S; Erdmann E;
Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
[TBL] [Abstract][Full Text] [Related]
14. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
15. Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge DJ
Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
[TBL] [Abstract][Full Text] [Related]
16. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
17. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
18. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of measurement of urinary albumin excretion in diabetes mellitus.
Stehouwer CD; Donker AJ
Neth J Med; 1993 Jun; 42(5-6):175-86. PubMed ID: 8377876
[TBL] [Abstract][Full Text] [Related]
20. Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa.
Marre M; Lièvre M; Vasmant D; Gallois Y; Hadjadj S; Reglier JC; Chatellier G; Mann J; Viberti GC; Passa P
Diabetes Care; 2000 Apr; 23 Suppl 2():B40-8. PubMed ID: 10860190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]